ReviewClinical pharmacokinetics2004
Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.
Review in Clinical pharmacokinetics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Interpretation of oral fluid tests for drugs of abuse.Annals of the New York Academy of Sciences · 2007Guideline
- The amphetamine response moderates the relationship between negative emotionality and alcohol use.Alcoholism, clinical and experimental research · 2013Trial
- Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.Clinical pharmacokinetics · 2011Trial
- Excretion of Delta9-tetrahydrocannabinol in sweat.Forensic science international · 2008Trial
- Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.Clinical chemistry · 2008Trial
- Review
- Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders.Clinical pharmacology : advances and applications · 2026Review
- Review
- Glutamate imbalance in key structure of the default mode network in adults with attention-deficit/hyperactivity disorder.European archives of psychiatry and clinical neuroscience · 2025Article
- Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.Disease-a-month : DM · 2025Review
- Medications for attention deficit hyperactivity disorder associated with increased risk of developing glaucoma.Eye (London, England) · 2024Article
- Enantiomer-specific analysis of amphetamine in urine, oral fluid and blood.Journal of analytical toxicology · 2024Article
- Protective effects of amphetamine and methylphenidate against dopaminergic neurotoxicants in SH-SY5Y cells.Current research in toxicology · 2024Article
- Analysis of 2,5-dimethoxy-amphetamines and 2,5-dimethoxy-phenethylamines aiming their determination in biological matrices: a review.Forensic toxicology · 2023Review
- Illegal drugs and periodontal conditions.Periodontology 2000 · 2022Review
- Temporal monitoring of stimulants during the COVID-19 pandemic in Belgium through the analysis of influent wastewater.The International journal on drug policy · 2022Article
- Toilet-based continuous health monitoring using urine.Nature reviews. Urology · 2022Review
- Altered metabolic pathways elucidated via untargeted in vivo toxicometabolomics in rat urine and plasma samples collected after controlled application of a human equivalent amphetamine dose.Archives of toxicology · 2021Article
- Article
- How Important Is the Use of Cocaine and Amphetamines in the Development of Parkinson Disease? A Computational Study.Neurotoxicity research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Consumption of amfetamine-type stimulants, including classical amfetamines and 'designer drugs', has been recognised as one of the most significant trends in drug abuse at the end of the past century and at the beginning of the current one. The first cause is the increasing consumption amongst youth of methylenedioxy- and methoxy-substituted amfetamines, of which the pharmacology in humans is currently under investigation. Secondly, the abuse of more classical amfetamines, such as amfetamine itself and metamfetamine, continues to be highly prevalent in some geographical regions. Amfetamines are powerful psychostimulants, producing increased alertness, wakefulness, insomnia, energy and self-confidence in association with decreased fatigue and appetite as well as enhanced mood, well-being and euphoria. From a clinical pharmacokinetic perspective, amfetamine-type stimulants are rather homogeneous. Their oral bioavailability is good, with a high distribution volume (4 L/kg) and low binding to plasma proteins (less than 20%). The elimination half-life is 6-12 hours. Both hepatic and renal clearance contribute to their elimination from the body. Hepatic metabolism is extensive in most cases, but a significant percentage of the drug always remains unaltered. Amfetamine and related compounds are weak bases, with a pKa around 9.9, and a relatively low molecular weight. These characteristics allow amfetamine-type stimulants to diffuse easily across cell membranes and lipid layers and to those tissues or biological substrates with a more acidic pH than blood, facilitating their detection in alternative matrices at relatively high concentrations. In most cases, the concentrations found are higher than expected from the Henderson-Hasselbach equation. Drug monitoring in non-conventional biological matrices (e.g. saliva, hair, nails, sweat) has recently gained much attention because of its possible applications in clinical and forensic toxicology. An individual's past history of medication, compliance or drug abuse can be obtained from testing of hair and nails, whereas data on current status of drug use can be provided by analysis of sweat and saliva. Because of the physicochemical properties of amfetamine-type stimulants, this group of drugs is one of the most suitable for drug testing in non-conventional matrices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.